Nicotinic acid plus simvastatin versus simvastatin alone in peripheral arterial disease with low HDL cholesterol

Phase 4, randomised, open-label trial in arteriosclerosis obliterans and dyslipidemia comparing Niaspan + simvastatin with Simvastatin monotherapy (2 arms). Primary endpoints: Change in carotid and femoral intima-media thickness and Major adverse cardiovascular events. Started Mar 2007; status: completed.